Philadelphia, PA- September 17, 2009
NextDocs Corporation announced enhancements to their partnership with Thomson Reuters, a leading source of intelligent information for businesses and professionals. Together, the companies have developed and demonstrated effective integration between the NextDocs Document and Quality Management System and the Thomson Reuters Liquent Regulatory software platform, providing a comprehensive solution for managing regulatory content from authoring to publishing and submission. In addition, the two companies also announced that NextDocs will support the Liquent SmartScribe® set of document templates from Thomson Reuters.
The integration between the NextDocs Document and Quality Management System and the Liquent InSight Platform allows the two systems to work from a common set of SharePoint-based documents. With SharePoint as a common repository, NextDocs system and theLiquent Regulatory Software are able to interact with one another; for example, organizations can access NextDocs documents housed in SharePoint and build an eCTD structure utilizing Thomson Reuters Liquent InSight Platform.
"Our Liquent InSight platform...provide[s] a single authoritative platform, which allows users to manage regulatory information through all stages of development, from early submissions to marketed registrations," said Rick Riegel, Vice President and General Manager, Services and Software Solutions at Thomson Reuters.
As part of the enhanced partnership, NextDocs will be offering Liquent SmartScribe® from Thomson Reuters. These templates enable users to create common technical documents quickly, efficiently and in a constant standard. The user friendly templates help to ensure all documents comply with format requirements.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.